摘要
表观遗传学沉默几乎是人类恶性肿瘤的普遍特征,其影响涉及从肿瘤起始到进展的所有关键信号通路,靶向表观遗传学异常具有巨大潜力.近年来,表观遗传学治疗药物DNA甲基转移酶抑制剂与组蛋白去乙酰化酶抑制剂单独或与其他治疗相结合,在一些血源性肿瘤及实体瘤中获得了突出的疗效,正在实现从实验室到临床的快速转化.本文就表观遗传学治疗药物单独及与其他治疗相结合在肿瘤基础与临床研究中的相关进展作一综述,以便发现并确定进一步的研究方向,加速其向肿瘤临床的转化.
Epigenetic gene silencing is an almost universal feature of human malignancies, and its effects involve all the critical signaling pathways from tumor initiation to progression. Targeting epigenetic abnormalities has great potentials for tumor therapy. In recent years, epigenetic therapeutic drugs DNA methyltransferase inhibitors and histone deacetylase inhibitors, alone or in combination with other treatments, have exhibited outstanding results in the therapy of some hematogenous and solid tumors, which are undergoing rapid transformation from bench science to clinical trials. In this article, we review the recent progress of epigenetic therapy, with an aim to highlight the further research directions and accelerate the clinical transformation of epigenetic therapy.
出处
《世界华人消化杂志》
CAS
2017年第12期1071-1078,共8页
World Chinese Journal of Digestology
